Angiotensin II Facilitates Breast Cancer Cell Migration and Metastasis

Breast cancer metastasis is a leading cause of death by malignancy in women worldwide. Efforts are being made to further characterize the rate-limiting steps of cancer metastasis, i.e. extravasation of circulating tumor cells and colonization of secondary organs. In this study, we investigated whether angiotensin II, a major vasoactive peptide both produced locally and released in the bloodstream, may trigger activating signals that contribute to cancer cell extravasation and metastasis. We used an experimental in vivo model of cancer metastasis in which bioluminescent breast tumor cells (D3H2LN) were injected intra-cardiacally into nude mice in order to recapitulate the late and essential steps of metastatic dissemination. Real-time intravital imaging studies revealed that angiotensin II accelerates the formation of metastatic foci at secondary sites. Pre-treatment of cancer cells with the peptide increases the number of mice with metastases, as well as the number and size of metastases per mouse. In vitro, angiotensin II contributes to each sequential step of cancer metastasis by promoting cancer cell adhesion to endothelial cells, trans-endothelial migration and tumor cell migration across extracellular matrix. At the molecular level, a total of 102 genes differentially expressed following angiotensin II pre-treatment were identified by comparative DNA microarray. Angiotensin II regulates two groups of connected genes related to its precursor angiotensinogen. Among those, up-regulated MMP2/MMP9 and ICAM1 stand at the crossroad of a network of genes involved in cell adhesion, migration and invasion. Our data suggest that targeting angiotensin II production or action may represent a valuable therapeutic option to prevent metastatic progression of invasive breast tumors.

[1]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[2]  D. Rowland,et al.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. , 2010, The Lancet. Oncology.

[3]  J. Greenwood,et al.  Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  J. Massagué,et al.  Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. , 2011, Cancer cell.

[5]  A. Vincent-Salomon,et al.  A “class action” against the microenvironment: do cancer cells cooperate in metastasis? , 2008, Cancer and Metastasis Reviews.

[6]  M. Qiao,et al.  Angiotensin II Type 1 Receptor Expression in Human Gastric Cancer and Induces MMP2 and MMP9 Expression in MKN-28 Cells , 2007, Digestive Diseases and Sciences.

[7]  R. Wirtz,et al.  Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[8]  Robert A. Weinberg,et al.  Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. , 2011, Seminars in cancer biology.

[9]  Sang Min Park,et al.  Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies , 2011, Canadian Medical Association Journal.

[10]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[11]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[12]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[13]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[14]  S. Umemura,et al.  Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis , 2007, Laboratory Investigation.

[15]  G. Naumov,et al.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. , 2002, Cancer research.

[16]  T. Matsuishi,et al.  Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. , 2003, The Journal of clinical investigation.

[17]  Rakesh K Jain,et al.  Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? , 2007, The Lancet. Oncology.

[18]  J. Chelly,et al.  Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy , 2011, Journal of Molecular Medicine.

[19]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[20]  L. Hunyady,et al.  Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. , 2006, Molecular endocrinology.

[21]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[22]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[23]  U. Lendeckel,et al.  Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread , 2007, Cancer biology & therapy.

[24]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[25]  Karl Swedberg,et al.  Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals , 2011, Journal of hypertension.

[26]  A. Vincent-Salomon,et al.  8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis , 2009, PloS one.

[27]  D. Khemasuwan,et al.  Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins , 2011, Cancer investigation.

[28]  M. Itoman,et al.  Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. , 2002, Biochemical and biophysical research communications.

[29]  J. Panés,et al.  Direct evidence of leukocyte adhesion in arterioles by angiotensin II. , 2004, Blood.

[30]  A. Miyajima,et al.  Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. , 2002, Cancer research.

[31]  C. Nahmias,et al.  Angiotensin receptors: a new role in cancer? , 2005, Trends in Endocrinology & Metabolism.

[32]  Alnawaz Rehemtulla,et al.  AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist , 2009, Proceedings of the National Academy of Sciences.

[33]  G. Vinson,et al.  Localisation of renin-angiotensin system (RAS) components in breast , 2006, British Journal of Cancer.

[34]  Mohamed Abdelkarim,et al.  Invading Basement Membrane Matrix Is Sufficient for MDA-MB-231 Breast Cancer Cells to Develop a Stable In Vivo Metastatic Phenotype , 2011, PloS one.

[35]  I. Witz.  Tumor-microenvironment interactions: dangerous liaisons. , 2008, Advances in cancer research.

[36]  R. Hannan,et al.  The renin–angiotensin system and cancer: old dog, new tricks , 2010, Nature Reviews Cancer.

[37]  D. Jenkins,et al.  Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice , 2005, Breast Cancer Research.

[38]  J. Kinoshita,et al.  Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. , 2009, International journal of oncology.